<DOC>
	<DOCNO>NCT00162656</DOCNO>
	<brief_summary>This international trial conduct three cooperative group : SFOP ( France , Belgium , Netherlands ) , CCG ( USA , Canada , Australia ) , UKCCSG ( UK Ireland ) . Children mature B-cell lymphoma/leukaemia stratify three different risk group ( A , B , C ) receive treatment progressive intensity . Randomized trial 2 big group ( B C ) test whether `` reduce '' therapy equivalent standard intensive therapy ( LMB-89 B C ) term event free survival . The reason modification reduce long term toxicity include cardiotoxicity , impaired fertility secondary malignancy . In group B , modification treatment consist reduction cyclophosphamide COPADM2 and/or elimination COPADM3 . In group C , modification consist reduction dos CYVE course elimination last 3 course maintenance treatment</brief_summary>
	<brief_title>Treatment Mature B-cell Lymphoma/Leukaemia</brief_title>
	<detailed_description>Group B : Randomized trial factorial design . The 4 treatment arm standard LMB89 therapy B , reduction cyclophosphamide ( CPM ) COPADM2 , deletion COPADM3 , reduction deletion . Randomization occur follow COPADM1 stratify national group , histology ( large cell ; small non cleave cell ) stage ( Murphy I orII ; Murphy III+LDH &lt; 2N ; Murphy III+LDH &gt; 2N Murphy IV ) . The primary analysis question whether reduce CPM dose COPADM2 result small long-term EFS whether omit COPADM3 result small long-term EFS Group C : Randomized trial . The 2 treatment arm standard LMB89 therapy C versus reduction CYVE + deletion last 3 maintenance course . Randomization occur follow COPADM2 stratify national group , histology ( large cell ; small non cleave cell ) CNS disease . The primary analysis question whether reduce CYVE omit last 3 maintenance course result small long-term EFS standard LMB 89 treatment C</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<criteria>Newly diagnose B lineage nonHodgkin 's lymphoma Revised European American Lymphoma ( REAL ) II 9 ( diffuse large cell lymphoma ) , 10 ( Burkitt 's lymphoma ) , 11 ( high grade B cell lymphoma , Burkitt 's like ) bone marrow &gt; 5 % L3 blast . Pre treatment image study adequate document Murphy disease stage Group B C patient eligible randomization ( Therapy stratification group : Group A=completely resect stage I completely resect abdominal stage II lesion , Group B= All case eligible Group A Group C , Group C= Any CNS involvement and/or bone marrow involvement Â³ 25 % blast ) Patients available minimum follow 36 month Informed consent prior study entry Anaplastic large cell Ki 1 positive lymphomas Previous chemotherapy . Congenital immunodeficiency Prior organ transplantation Previous malignancy type Known HIV positivity</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>20 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>B-Cell Lymphoma</keyword>
</DOC>